Covered recipient · General Payments record
RICHARD A JACKSON
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$3,346.49
165 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,626.50 | 163 |
| Consulting Fee | $640.00 | 1 |
| Education | $79.99 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RICHARD A JACKSON
NPI 1578644290 · CMS profile ID 344186
Allopathic & Osteopathic Physicians / Internal Medicine
RICHMOND, VA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1578644290?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RICHARD A JACKSON, NPI 1578644290, CMS profile ID 344186. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578644290?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). RICHARD A JACKSON, NPI 1578644290, CMS profile ID 344186. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578644290?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- RICHARD A JACKSON, NPI 1578644290, CMS profile ID 344186, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578644290?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
165 matching records · $3,346.49 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 165.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $17.54 | 08/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789132215 | CMS |
| AbbVie Inc. | $18.51 | 08/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932819 | CMS |
| GlaxoSmithKline, LLC. | $0.69 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803049495 | CMS |
| GlaxoSmithKline, LLC. | $11.62 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803081679 | CMS |
| AbbVie Inc. | $4.31 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932815 | CMS |
| Biohaven Pharmaceuticals, Inc. | $15.14 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852525741 | CMS |
| AbbVie Inc. | $12.39 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932811 | CMS |
| AbbVie Inc. | $16.11 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932807 | CMS |
| Amgen Inc. | $15.50 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825718875 | CMS |
| AbbVie Inc. | $15.01 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932803 | CMS |
| Astellas Pharma US Inc | $15.05 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821377985 | CMS |
| Alexion Pharmaceuticals, Inc. | $19.71 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783134931 | CMS |
| Mylan Specialty L.P. | $14.30 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965423585 | CMS |
| AbbVie Inc. | $14.08 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932799 | CMS |
| AstraZeneca Pharmaceuticals LP | $640.00 | 07/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829353631 | CMS |
| Biohaven Pharmaceuticals, Inc. | $23.61 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852525739 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.87 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850410597 | CMS |
| AbbVie Inc. | $13.93 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932795 | CMS |
| AbbVie Inc. | $3.77 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932791 | CMS |
| Novartis Pharmaceuticals Corporation | $12.07 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812730169 | CMS |
| AbbVie Inc. | $14.77 | 07/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932787 | CMS |
| Amarin Pharma Inc. | $20.64 | 07/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815121893 | CMS |
| GlaxoSmithKline, LLC. | $10.55 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802988837 | CMS |
| AbbVie Inc. | $19.65 | 06/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932783 | CMS |
| Amgen Inc. | $13.45 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825718887 | CMS |
| Mylan Specialty L.P. | $12.15 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965420235 | CMS |
| Merck Sharp & Dohme Corporation | $13.30 | 06/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848412855 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $8.60 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850393683 | CMS |
| AbbVie Inc. | $14.73 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932779 | CMS |
| Janssen Pharmaceuticals, Inc | $11.44 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788407099 | CMS |
| AbbVie Inc. | $3.56 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932775 | CMS |
| AbbVie Inc. | $13.88 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932771 | CMS |
| AbbVie Inc. | $3.82 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932767 | CMS |
| Vanda Pharmaceuticals Inc. | $22.37 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838902201 | CMS |
| Sunovion Pharmaceuticals Inc. | $18.01 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821720827 | CMS |
| AbbVie Inc. | $12.07 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932763 | CMS |
| AbbVie Inc. | $12.39 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932759 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.28 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829566113 | CMS |
| PFIZER INC. | $14.04 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833454877 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.79 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850035977 | CMS |
| AbbVie Inc. | $19.10 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932755 | CMS |
| Astellas Pharma US Inc | $11.67 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821377981 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.04 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830108635 | CMS |
| AbbVie Inc. | $14.15 | 05/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932751 | CMS |
| AbbVie Inc. | $23.17 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794932747 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.81 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829424429 | CMS |
| GlaxoSmithKline, LLC. | $5.96 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802891591 | CMS |
| Esperion Therapeutics, Inc. | $11.87 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838318695 | CMS |
| GlaxoSmithKline, LLC. | $16.72 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802603177 | CMS |
| Insulet Corporation | $14.11 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839825421 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $536,919.14 | 38 |
| PY2024 | Principal investigator | $430,772.86 | 52 |
| PY2023 | Recipient | $2,912.76 | 2 |
| PY2023 | Principal investigator | $735,676.95 | 111 |
| PY2022 | Recipient | $8,126.00 | 2 |
| PY2022 | Principal investigator | $279,780.82 | 157 |
| PY2021 | Recipient | $1,684.04 | 1 |
| PY2021 | Principal investigator | $75,744.80 | 5 |
| PY2020 | Principal investigator | $141,499.58 | 210 |
| PY2019 | Principal investigator | $289,719.52 | 138 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
38 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $9,108.34 | 12/31/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC. | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1232920560 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 12/11/2025 | Non-covered Recipient Entity Dominion Medical Associates Inc-Downtown | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220996970 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Dominion Medical Associates Inc-Downtown | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220715913 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 11/25/2025 | Non-covered Recipient Entity Dominion Medical Associates Inc-Downtown | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220806709 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $36.81 | 11/15/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190302899 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $9,800.00 | 11/05/2025 | Non-covered Recipient Entity Dominion Medical Associates - ClinEdge - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508485 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,598.00 | 11/05/2025 | Non-covered Recipient Entity Dominion Medical Associates - ClinEdge - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508489 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,639.24 | 11/05/2025 | Non-covered Recipient Entity EAST FLORIDA EYE INSTITUTE | A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) | No dispute reported | 06/30/2026 | 1190309444 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Dominion Medical Associates Inc-Downtown | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220715905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 11/01/2025 | Non-covered Recipient Entity Dominion Medical Associates Inc-Downtown | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220715907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 11/01/2025 | Non-covered Recipient Entity Dominion Medical Associates Inc-Downtown | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220715909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 11/01/2025 | Non-covered Recipient Entity Dominion Medical Associates Inc-Downtown | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220715911 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,697.00 | 10/15/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185541052 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,040.76 | 10/08/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190302895 |
| Principal investigator 1 | Eli Lilly and Company | $17,714.00 | 10/07/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR EVENT – MOVE-LP(A) | No dispute reported | 06/30/2026 | 1187879961 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,000.00 | 10/01/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure | No dispute reported | 06/30/2026 | 1190304009 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,800.00 | 10/01/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES INC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309446 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $912.59 | 09/03/2025 | Non-covered Recipient Entity EAST FLORIDA EYE INSTITUTE | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190313579 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,065.00 | 06/12/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190304007 |
| Principal investigator 1 | Eli Lilly and Company | $225.00 | 04/23/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187878857 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,405.61 | 03/31/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190302893 |
| Principal investigator 1 | Novo Nordisk AS | $17,521.85 | 03/31/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1213819918 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,876.89 | 03/11/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190304001 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $44,930.04 | 03/05/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190302897 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $40,475.24 | 03/03/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES INC. | A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214124540 |
| Principal investigator 1 | Novo Nordisk AS | $1,700.00 | 02/21/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1213727367 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $14,472.54 | 02/06/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190302903 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43,958.04 | 02/04/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190304005 |
| Principal investigator 1 | Novo Nordisk AS | $525.00 | 01/31/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1213773687 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,376.00 | 01/30/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190303999 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,013.85 | 01/29/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185541050 |
| Principal investigator 1 | Eli Lilly and Company | $33,900.00 | 01/28/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187883652 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,290.00 | 01/28/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190304003 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,110.47 | 01/15/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190302901 |
| Principal investigator 1 | Eli Lilly and Company | $1,476.00 | 01/09/2025 | Non-covered Recipient Entity LIGHTSHIP INC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187885984 |
| Principal investigator 1 | Eli Lilly and Company | $7,338.00 | 01/07/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187881142 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,000.00 | 01/07/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES, INC | A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension | No dispute reported | 06/30/2026 | 1190304011 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $125,614.70 | 01/01/2025 | Non-covered Recipient Entity DOMINION MEDICAL ASSOCIATES INC. | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214125404 |